The 2025-2030 Pharma Patent Cliff: Which Drugs Face Generic Entry?

Between 2025 and 2030, the pharmaceutical industry faces its largest patent cliff in history. Drugs generating over $200 billion in combined annual peak revenue will lose exclusivity – opening the door to generic and biosimilar competition.

This is not a gradual transition. Several of the industry’s highest-revenue products face expiry within a concentrated 3-year window. For portfolio analysts, investors, and strategy teams, understanding which drugs are affected, when exclusivity ends, and how quickly generics or biosimilars can enter is essential for risk assessment and planning.

This article maps the major patent cliffs by year, drug, company, and therapy area. It provides the data framework portfolio analysts need to assess revenue exposure and anticipate competitive shifts.

The Problem: This Patent Cliff Is Larger and More Concentrated

Pharma has navigated patent cliffs before. The 2010-2015 cycle saw Lipitor, Plavix, and several blockbusters lose protection. However, the 2025-2030 cliff differs in three critical ways.

Scale. The cumulative revenue at risk exceeds $200 billion – roughly 2.5x the previous major cliff. This reflects growing dependence on a small number of mega-blockbusters.

Concentration. A disproportionate share falls in 2025-2028. Five drugs alone represent over $80 billion in annual revenue at risk.

Biologic complexity. Unlike the 2010-2015 cliff dominated by small molecules, the 2025-2030 cliff includes several biologics. Biosimilar entry is slower, more expensive, and less predictable than generic entry.

The Insight: Patent Expiry Date Is Not Revenue Loss Date

A common mistake is treating the patent expiry date as when revenue drops. The relationship between expiry and erosion depends on several factors.

For small molecules: Generic entry typically happens within 6-12 months. Revenue erosion is fast – often 70-90% within two years.

For biologics: Biosimilar entry takes longer due to manufacturing complexity and regulatory requirements. Erosion is slower – 30-50% in the first two years, increasing to 60-80% over five years.

For drugs with patent estates: Secondary patents can delay generic entry by 1-3 years through litigation, even after the primary patent expires.

The real insight: Portfolio analysts who model exposure based only on primary patent expiry dates consistently overestimate the speed of revenue loss for biologics and underestimate it for small molecules with thin estates. Accurate modeling requires drug-by-drug analysis.

The Data: Major Patent Cliffs 2025-2030

Decision Intelligence: How to Assess Portfolio Exposure

For portfolio analysts, five questions determine the accuracy of your model.

1. What is the patent estate depth? Map every relevant patent, not just the compound patent.

2. Are Paragraph IV filings active? For small molecules, these are the strongest signal of upcoming generic competition.

3. How many biosimilar developers are active? More developers means faster and deeper erosion after entry.

4. What is the switching behavior? Some therapy areas show slower biosimilar adoption due to physician inertia.

5. Does the company have lifecycle management strategies? Line extensions and next-generation products affect how much revenue transfers to generics.

The Value: What Accurate Analysis Enables

Portfolio risk quantification. Accurate analysis distinguishes “patent expires in 2026” from “meaningful revenue impact begins in 2028” – a distinction worth billions in valuation models.

M&A target identification. Patent cliff data identifies which companies need pipeline most urgently. These are the most likely aggressive buyers.

Competitive strategy. For generic and biosimilar companies, accurate timing determines where to invest development resources.

Example: Modeling Eliquis Revenue Erosion

Basic analysis: Eliquis patent expires 2025. Peak revenue $20B+. Generic entry expected. Model projects 80% revenue loss within 2 years. Total exposure: $16B.

Accurate analysis: Eliquis has multiple patents expiring 2025-2031. Paragraph IV filings are active but litigation ongoing. First generic entry may happen 2025-2026, but settlements could grant authorized generics. BMS/Pfizer are launching a reformulated version. Realistic model: 40-50% erosion Year 1, 60-75% Year 2, 80%+ only by Year 3-4.

The basic model overestimates near-term impact by $4-8 billion annually. That difference changes the valuation thesis entirely.

Conclusion

The 2025-2030 pharma patent cliff is the largest in history – over $200 billion in combined peak revenue at risk. The peak exposure window is 2025-2028, with Keytruda representing the single largest individual risk.

Patent expiry dates alone do not determine revenue impact timing. Patent estate depth, biosimilar development activity, Paragraph IV filings, and switching behavior all modify the erosion curve. Accurate risk assessment requires drug-by-drug analysis.

Build a deeper understanding of patent strategy. Explore drug patent basics and how data exclusivity differs from patent protection for the foundational IP concepts that drive these dynamics.

Frequently Asked Questions

How the Patent Cliff Creates M&A Opportunities

The patent cliff directly drives pharma acquisition activity. When a major drug faces exclusivity loss in 3-5 years, the company holding that asset needs replacement revenue. The fastest path is acquisition of a mid-to-late stage asset that can be approved before or shortly after the cliff event. This creates a predictable pipeline of acquisition demand that BD teams can anticipate. If you track which major drugs are approaching exclusivity loss (using databases like Evaluate Pharma or Citeline) and cross-reference with the acquirer’s pipeline gaps, you can predict acquisition targets and approaches with reasonable accuracy 2-3 years before the deal occurs.

Patent Cliff Planning for Commercial Teams: The 36-Month Framework

Commercial teams typically have 36 months from patent expiry to maximise revenue from the branded product. Month 1-12: defend market share aggressively through payer contracting, patient support programmes, and physician loyalty initiatives before generic entry. Month 13-24: transition highest-value patients to any successor product available. Adjust pricing strategy as generic erosion begins. Month 25-36: focus remaining branded marketing investment on segments where substitution has not occurred (specialty channels, markets with delayed generic entry, payer-protected segments). By month 36, accept that the market has transitioned and redirect investment to successor products.

What the Patent Cliff Means for Pharma BD Priorities in 2026

The patent cliff is not just a threat to existing revenue – it is the most reliable predictor of what large pharma will pay for in the next 24-36 months. Companies facing cliff events need assets that can be approved in time to replace revenue, which means late Phase 2 or Phase 3 assets in indications with clear regulatory pathways. BD teams at smaller biotechs should align their out-licensing strategy with the published cliff timelines of their target partners. An asset in Phase 2 for an indication that matches a major pharma’s cliff exposure in 2028 is worth significantly more today than the same asset in a less urgent indication.